logo-loader
ASX:IMU

Imugene Ltd

Receive alerts
Market:
ASX
Market Cap:
$154.91 m
Price
0.04 AUD
Change
2.94%
52 weeks high
0.06
52 weeks low
0.02

Imugene is a publicly-listed biotechnology company with operations in America and Europe, developing cancer immunotherapies targeting B-cell peptide vaccines.

Oncolytic Virus

CF33

Our lead candidate is a chimeric vaccinia (pox) virus known as CF33, developed by Professor Yuman Fong, at the prestigious City of Hope Comprehensive Cancer Center in Los Angeles, California.

Vaccinia is a genetically stable double stranded DNA virus of the Poxviridae family. It has a track record of safe use in millions of humans as it was the active constituent of the vaccine that eradicated smallpox, one of the most devastating diseases known to humanity and was the first oncolytic virus demonstrating viral oncolysis in the laboratory in 1922.

(click here for more information)


B-Cell Immunotherapies

B-cell immunotherapies link an immunogenic protein with a B-cell epitope and incorporate an adjuvant to produce a B-cell cancer vaccine that induces the body to produce antibodies against the normal self-proteins, such as HER2 or PD-1 (known as breaking immune tolerance). The antibodies produced following the vaccination are a ‘polyclonal’ mixture of antibodies that bind to different parts of the vaccine antigen. This makes them somewhat different to the monoclonal antibody drugs, even though they bind to the same target in the body.

(click here for more information)


Technology: Mimotopes

Mimotopes are peptides that mimic the effects of specific B-cell epitopes in stimulating an immune response. Immunization with such mimotopes would be expected to induce an immune response directed at the target disease related antigen. As such they have great utility as potential immunotherapeutic approaches for various cancers in much the same way as HER-Vaxx is being used to stimulate an immune response to the tumour antigen HER2 in breast or gastric cancer.

Using a proprietary screening platform, it has been possible to screen libraries of peptides using antibodies for candidates that mimic the effect of target epitopes. Imugene has acquired an option to continue this research and development of Mimotope Vaccines with the Company’s scientific team in Austria.


Last updated 11th March 2020

Leslie Chong
CEO & Managing Director

Ms Chong has over 20 years of oncology experience in Phase I – III of clinical program development, including leadership role involvement in two marketed oncology products. She was previously Senior Clinical Program Lead at Genentech, Inc., in San Francisco. Genentech is widely regarded as one of the world’s most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin.


Paul Hopper
Executive Director

Mr Hopper has international & ASX biotech capital markets experience, particularly in immuno-oncology & vaccines. He is the former Chairman of Viralytics (acquired in June 2018 by Merck for $500m), Founder & Director of Prescient, Founder of Imugene & Polynoma LLC, former Director pSivida, Somnomed & Fibrocell Science.


Dr Axel Hoos
Non-Executive Director

Dr Axel Hoos is Senior Vice President and Head of Oncology at GSK. Before his current role, he was at Bristol-Myers Squibb where he was Medical Lead for the development of the Yervoy, the first survival-improving medicine in immuno-oncology. He is Chairman of the Board of the Sabin Vaccine Institute and Co-Chair of the Cancer Immunotherapy Consortium Think-Tank.


Charles Walker
Non-Executive Director

Mr Walker is an experienced listed biotech CEO and CFO, He is experienced in financial markets including executing 55 international tech corporate transactions. His clinical experience includes managing pipeline of drugs in all stages from discovery, through to Phase III and to launched products.
 

Dr. Lesley Russell
Non-Executive Director

Dr. Lesley Russell has more than 25 years of international operational and leadership experience with a number of established and emerging pharmaceutical companies across multiple therapeutic areas including oncology and haematology.

Her experience has been gained at a number of leading companies including, Amgen (NASDAQ: AMGN), Eli Lilly (NASDAQ: LLY), US Bioscience/Medimmune Oncology, Cephalon Inc (NASDAQ: CEPH), Teva Pharmacaeuticals (NASDAQ: TEVA), TetraLogic and Innocoll Holdings Plc.

Dr. Lesley Russell is currently a Non-executive Director of AMAG Pharmaceuticals (NASDAQ:AMAG), Enanta Pharmaceuticals (NASDAQ:ENTA) and Sojournix a privately held biotechnology company. Dr. Lesley Russell was a non-executive director of Endocyte Pharmaceuticals Inc until its acquisition by Novartis in December, 2018.


Dr Jens Eckstein
Non-Executive Director

Dr Jens Eckstein is an established international venture investor and active mentor of life science entrepreneurs and start-up teams.

Jens is currently Managing Partner of Apollo Ventures a venture firm focusing on age-related diseases and health span. Before joining Apollo he was president of SROne for eight years. SR One is the corporate venture capital arm of global pharmaceutical giant GlaxoSmithKline which invests in emerging life science companies pursuing innovative science with significant impact on medical care and patients.

Jens is also a founder and co-founder of several innovative life science and health care information technology companies as well as being the creator of OneStart, the world’s largest life science and healthcare start-up accelerator program.

Dr Eckstein brings more than 15 years of venture capital funding of earlier-stage biopharmaceutical companies, technology transfer, operational and research management experience in drug discovery and biotechnology.

He has served on the boards of several listed and private biotechnology companies including Palleon Pharma, Gladius Pharmaceuticals and Decibel Therapeutics.

He has served on the boards of ZappRx, Thrasos Therapeutics and Alios Biopharma (acquired by Johnson & Johnson in 2014).

Jens is a Kaufman Fellow, founder of Action Potential Venture Capital (APVC) and has held senior roles with the trans-Atlantic venture capital firm TVM Capital.

In addition, he holds several issued patents and has authored over 25 scientific publications. He earned his Doctorate, summa cum laude, in Biological Chemistry in at the University of Konstanz and Harvard University.


Last updated 11th March 2020

Head Office:

37 Bligh Street
Suite 1006, Level 10
Sydney NSW 2000
Australia

Email: [email protected]


Registered Office:

62 Lygon Street, Level 3
Carlton VIC 3053
Australia

Phone: +61.3.9824.5254

ABN: 99 009 179 551


Share Registry:

Automic Registry Services
Level 1, 7 Ventnor Avenue
West Perth WA 6005
Australia

Phone: +61.8.9324.2099
Fax: +61.8.9321.2337

Website: www.automic.com.au
ASX Code: IMU


Postal address:

P.O. Box 655
Carlton South VIC 3053
Australia

 

Last updated 11th March 2020